Corcept Therapeutics reported second quarter 2026 financial results, posting revenue of $256.1 million, a 32 percent increase from the prior year period. Net income reached $43.0 million, or $0.36 per diluted share, compared to $35.1 million in Q2 2025. The company raised its full-year 2026 revenue guidance to $1.1–$1.2 billion from previous estimates. Korlym and authorized generic product revenue totaled $208.6 million, while Lifyorli generated $47.6 million in its first quarter of availability following FDA approval in March 2026. Operating expenses increased to $214.8 million due to launch costs for Lifyorli and investments in the Cushing’s syndrome business. The company holds $544.6 million in cash and investments as of June 30, 2026. Corcept Therapeutics is a commercial-stage biopharmaceutical company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating cortisol effects.

Corcept Therapeutics Incorporated resubmitted its New Drug Application to the U.S. Food and Drug Administration for relacorilant to treat Cushing's syndrome. Corcept Therapeutics is a biopharmaceutical company focused on developing and commercializing specialized medicine for endocrine and endocrine-related disorders.